Tacrolimus combined with low-dose corticosteroids is an effective and safe therapeutic option for refractory IgA nephropathy.
Tacrolimus (TAC) has been shown to improve remission from proteinuria in patients with refractory IgA nephropathy (IgAN); however, the efficacy and safety of TAC in such patients have not been fully explored. Therefore, the present study was conducted to evaluate the tolerance to and efficacy of TAC combined with low-dose corticosteroids in patients with refractory IgAN. This was a single-center retrospective study. A total of 28 patients with refractory IgAN were randomly included and received TAC plus corticosteroid; 26 patients received TAC and prednisone, and 2 patients received TAC and methylprednisolone. In addition, all patients were treated with an angiotensin inhibitor. Total urinary protein excretion, serum albumin, blood glucose, complete remission (CR), partial remission (PR), cholesterol, low-density lipoprotein (LDL), serum creatinine (Scr) and estimated GFR (eGFR) were tested at baseline and at 3, 6 and 12 months after the initiation of treatment in all patients. The primary endpoints were CR and PR. Secondary endpoints included changes of Scr, eGFR, clinical data and adverse events. After 12 months, CR was achieved in 40.1% of patients and PR in 43.4%, yielding a total response rate of 83.5%, and the total urinary protein excretion, serum albumin, cholesterol and LDL results were improved significantly compared with those at baseline. Proteinuria and serum albumin results were significantly improved by month 3 of treatment. Two patients relapsed during months 3-6 of follow-up. At the 12-month follow-up, renal function was improved compared with the baseline level as evidenced by eGFR and Scr, respectively. The blood glucose level was stable. One case of pneumococcal pneumonia developed in a patient treated with TAC plus low-dose methylprednisolone and one case of upper gastrointestinal hemorrhage was found in a patient treated with TAC plus low-dose prednisone; both cases completely recovered after treatment. In conclusion, TAC combined with low-dose corticosteroids may be an effective and safe therapeutic option for the treatment of refractory IgAN. However, given the small number of patients in this study, further prospective randomized controlled trials are required with a larger sample of participants and longer follow-up period.
Department of Nephrology, Shenzhen Second People's Hospital, Shenzhen, Guangdong 518035, P.R. China.
Qi-Jun
QJ
Wan
Department of Nephrology, Shenzhen Second People's Hospital, Shenzhen, Guangdong 518035, P.R. China.
Hao-Fei
HF
Hu
Department of Nephrology, Shenzhen Second People's Hospital, Shenzhen, Guangdong 518035, P.R. China.
Yong-Cheng
YC
He
Department of Nephrology, Shenzhen Second People's Hospital, Shenzhen, Guangdong 518035, P.R. China.
Shao-Dong
SD
Luan
Department of Nephrology, Shenzhen Second People's Hospital, Shenzhen, Guangdong 518035, P.R. China.
Hong-Tao
HT
Chen
Department of Nephrology, Shenzhen Second People's Hospital, Shenzhen, Guangdong 518035, P.R. China.
Tong
T
Li
Department of Nephrology, Shenzhen Second People's Hospital, Shenzhen, Guangdong 518035, P.R. China.
Yi
Y
Xu
Department of Nephrology, Shenzhen Second People's Hospital, Shenzhen, Guangdong 518035, P.R. China.
Hui-Li
HL
Xu
Department of Nephrology, Shenzhen Second People's Hospital, Shenzhen, Guangdong 518035, P.R. China.
Ying
Y
Liao
IgA nephropathy; adverse events; methylprednisolone; prednisone; renal pathology; tacrolimus